Please use this identifier to cite or link to this item:
|Title:||Effects of testosterone treatment on glucose metabolism and symptoms in men with type 2 diabetes and the metabolic syndrome: a systematic review and meta-analysis of randomized controlled clinical trials.|
|Authors:||Grossmann, Mathis;Hoermann, Rudolf;Wittert, Gary;Yeap, Bu B|
|Affiliation:||Department of Endocrinology, Austin Health, Heidelberg, Victoria, Australia|
Department of Medicine, Austin Health, The University of Melbourne, Heidelberg, Victoria, Australia
Discipline of Medicine, Royal Adelaide Hospital, University of Adelaide, Adelaide, SA, Australia
School of Medicine and Pharmacology, University of Western Australia, Perth, WA, Australia
Department of Endocrinology and Diabetes, Fremantle and Fiona Stanley Hospitals, Perth, WA, Australia
|Citation:||Clinical Endocrinology 2014; 83(3): 344-51|
|Abstract:||The effects of testosterone treatment on glucose metabolism and other outcomes in men with type 2 diabetes (T2D) and/or the metabolic syndrome are controversial.To perform a systematic review and meta-analysis of placebo-controlled double-blind randomized controlled clinical trials (RCT) of testosterone treatment in men with T2D and/or the metabolic syndrome.A systematic search of RCTs was conducted using Medline, Embase and the Cochrane Register of controlled trials from inception to July 2014 followed by a manual review of the literature.Eligible studies were published placebo-controlled double-blind RCTs published in English.Two reviewers independently selected studies, determined study quality and extracted outcome and descriptive data.Of the 112 identified studies, seven RCTs including 833 men were eligible for the meta-analysis. In studies using a simple linear equation to calculate the homeostatic model assessment of insulin resistance (HOMA1), testosterone treatment modestly improved insulin resistance, compared to placebo, pooled mean difference (MD) -1·58 [-2·25, -0·91], P < 0·001. The treatment effect was nonsignificant for RCTs using a more stringent computer-based equation (HOMA2), MD -0·19 [-0·86, 0·49], P = 0·58). Testosterone treatment did not improve glycaemic (HbA1c) control, MD -0·15 [-0·39, 0·10], P = 0·25, or constitutional symptoms, Aging Male Symptom score, MD -2·49 [-5·81, 0·83], P = 0·14).This meta-analysis does not support the routine use of testosterone treatment in men with T2D and/or the metabolic syndrome without classical hypogonadism. Additional studies are needed to determine whether hormonal interventions are warranted in selected men with T2D and/or the metabolic syndrome.|
|Appears in Collections:||Journal articles|
Files in This Item:
There are no files associated with this item.
Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.